drugset / Trial / NCT07858123
Safety and Efficacy Comparison Between CHF5993 100/6 12.5µg pMDI to Seretide Evohaler 125/25µg pMDI in Adolescent Subjects With Asthma
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The CLI-05993AA5-06 study is an interventional study designed to investigate the safety and efficacy of a new experimental drug called CHF5993 pMDI compared to the currently approved Seretide 125 Evohaler pMDI in adolescent patients with uncontrolled asthma.
Timeline
- Start
- 2026-11-16
- Primary completion
- 2030-06-26
- Completion
- 2030-06-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fluticasone propionate | Other / unclassified | 125 ug | Inhaled |
| Subject | Formoterol | Other / unclassified | 6 ug | Inhaled |
| Subject | Glycopyrronium | Unknown | 12.5 ug | Inhaled |
| Subject | beclomethasone dipropionate | Other / unclassified | 100 ug | Inhaled |
| Comparator | salmeterol xinafoate | Unknown | 25 ug | Inhaled |